|Age:||18 years or older|
|Keywords:||Primary Biliary Cholangitis, Moderate to Severe Hepatic Impairment, liver function, liver|
|Type:||Drug study, Phase 4|
The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.
2 mg/dL (178 μmol/L)